AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023.

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada's leadership in clinical research, manufacturing, and drug development. Over the next eight years, AbCellera plans to invest CA$401 million in the project, and the Governments of Canada and British Columbia will con.

AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients

PROCEPT BioRobotics Corp

LiveRamp Holdings Inc

Silicon Motion Technology

Hesai Group

Kymera Therapeutics

Schrodinger 

While the recent slow activity in the major indices clouds the narrative, you can still enjoy opportunities for growth stocks that could double your money. To be sure, you must be willing to accept some risks.

7 Growth Stocks That Could Double Your Money in 2023

AbCellera reported results from the first quarter on May 4th. To put it bluntly, the actual earnings print means next to nothing in this name at this stage. The company had a very busy and productive quarter under the surface, reporting progress on multiple fronts, specifically the TCE program (T-cell engager).

AbCellera Biologics: TCE Program Alone Could Be Worth More Than The Current Market Cap

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Andrea Tan - Goldman Sachs Antonia Borovina - Bloom Burton Stephen Willey - Stifel Nishant Gandhi - Truist Gaurav Goparaju - Berenberg Puneet Souda - SVB Securities Malcolm Hoffman - BMO Steven Mah - Cowen Operator Good afternoon. And welcome to AbCellera's First Quarter 2023 Business Update Conference Call.

AbCellera Biologics Inc. (ABCL) Q1 2023 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago.

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q1 2023 Business Results.

AbCellera Reports Q1 2023 Business Results

AbbVie

Amazon

Intuitive Surgical

Microsoft

Cloudflare

AI is advancing everything from health care to banking. This isn't new, but it is hitting the mainstream consciousness.

How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies

AbCellera Biologics Inc. (ABCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ambev

Gerdau

Navitas Semiconductor Corp

Arhaus

Momo

Super Group SGHC Ltd

Generally speaking, you get what you pay for, which on paper doesn't bode well for these bargain stocks under $10. Nevertheless, with thousands upon thousands of tradable securities available to public investors, at least a few will go unnoticed.

7 Stocks Under $10 That Analysts Love

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023

Alphabet

Alphabet has multiple ways to profit from greater use of AI in the healthcare sector. Intuitive Surgical is working on using AI to improve robotic surgery.

1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy

AdTheorent Holding Company Inc

B2Gold

Hudson Technologies

Radiant Logistics

TDCX

Although financial advisors often direct you to established, reliable enterprises, in some cases, you can find compelling ideas among the best stocks under $10. To be fair, such companies tend to be more volatile than your standard blue-chip fare.

7 Best Stocks Under $10 to Buy in April

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the 2023 Bloom Burton & Co.

AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023

Chimerix

Kiniksa Pharmaceuticals Ltd

Ocuphire Pharma

Point Biopharma Global

Vaccitech

Vir Biotechnology

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

Analog Devices

Alexandria Real Estate Equities

Anheuser-Busch InBev

Coda Octopus Group

Canadian Pacific Kansas City Limited

Charles River Laboratories

salesforce.com

CrowdStrike

Dominion Energy

Datadog

Diageo

Disney

Dynatrace Inc

Duke Energy

Essex Property Trust

Cedar Fair

General Mills

Corning

Hannon Armstrong Sustainable Infrastructure Capital

Honeywell

Intel

Most readers follow my work for the extensive writing I have done referencing my aggressive growth portfolio. However, the vast majority of my net worth is held in my all-weather portfolio. In this article, I would like to draw back the curtain on my main, all-weather portfolio, where roughly 80% of my assets reside.

Confounded's Complete All-Weather Portfolio Revealed

Evolution Petroleum

VAALCO Energy

Sensus Healthcare

If you aspire to one day topple entrepreneurial genius Elon Musk on the net wealth rankings through the equities market exclusively, you're obviously going to need to conduct heavy research on the stocks that can make you rich. However, you also want to be smart about this.

7 Stocks to Bet On if You Want to Be Richer Than Elon Musk

VANCOUVER, British Columbia & LONDON--(BUSINESS WIRE)---- $ABCL--AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023

AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2022 Earnings Conference Call February 21, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer, and President Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse Andrea Tan - Goldman Sachs Gary Nachman - BMO Robyn Karnauskas - Truist Gaurav Goparaju - Berenberg Antonia Borovina - Bloom Burton Operator Good afternoon. And welcome to AbCellera's Full-Year 2022 Business Update Conference Call.

AbCellera Biologics Inc (ABCL) Q4 2022 Earnings Call Transcript

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2022 Business Results

AbCellera Reports Full Year 2022 Business Results

BioNTech SE

iTeos Therapeutics, Inc.

Moderna

Regeneron Pharmaceuticals

You don't have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science.

The 7 Most Undervalued Biotech Stocks to Buy in February 2023

News for AbCellera Biologics Stock (ABCL)